R&D channel feed – Endpoints News

R&D channel feed

AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails and shares plunge

8 years ago

Dynavax shares slide as FDA review spotlights a hazy safety issue for Heplisav

8 years ago

Tetraphase lines up a new FDA pitch for antibiotic after it comes through in latest PhIII

8 years ago

GSK CEO Walmsley is reorganizing R&D, dropping drugs and adding a new focus on cancer research

8 years ago

Neuralstem’s lead drug crumbles in PhII, adding to a litany of failures for depression drugs and blasting shares

8 years ago

Biogen lays out a plan to “streamline” ops, add $400M to fund neurosciences R&D, new deals

8 years ago

Restructuring the pipeline, Eli Lilly says a baricitinib comeback in rheumatoid arthritis could take years

8 years ago

Novavax makes a case for a do-over on its failed RSV vaccine — but it's an uphill climb

8 years ago

Trading places with Bristol-Myers, Merck hit with another late-stage setback on checkpoint star Keytruda

8 years ago

Troubled Teva brings out the ax as it cuts deep into its Israeli pharma group

8 years ago

Another micro-cap biotech has flunked a pivotal test for a regenerative cell therapy

8 years ago

Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug

8 years ago

Nektar’s pitch on early cancer drug OK runs into a regulatory brick wall

8 years ago

Heartburn: Ironwood shares sink after blockbuster contender disappoints on a key goal in PhIIb

8 years ago

Researchers plot a course into PhIII after another Alzheimer’s drug flunks a key test

8 years ago

Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab

8 years ago

Paratek goes 3-for-3 in PhIII, but antibiotic stumbles on side effect profile

8 years ago

Back from the dead: Nektar hunts a blockbuster deal as opioid '181 looks less addictive than oxy

8 years ago

King cancer: The top 10 therapeutic areas in biopharma R&D

8 years ago

CymaBay shares get a bounce on positive PBC PhII data

8 years ago

FDA's Scott Gottlieb is fielding a new team of recruiters to start scouting top talent

8 years ago

FDA embraces the first US application for a gene therapy, offering an accelerated test case

8 years ago

FDA advisers back Novartis’ game-changing personalized CAR-T for cancer, approval in sight

8 years ago

D-day: Novartis arrives at a crossroad in the blockbuster race to win the first FDA OK for CAR-T

8 years ago

First page Previous page 292 293 294295296 297 298 Next page Last page